June 28, 2020 / 10:06 AM / 13 days ago

BRIEF-Staidson, Unit Get Approval From Indonesia Authorities To Run Phase 2 Clinical Trial For Its Monoclonal Antibody Drug BDB-001

June 28 (Reuters) - Staidson Beijing Biopharmaceuticals Co Ltd:

* SAYS IT, UNIT WIN APPROVAL FROM INDONESIA AUTHORITIES TO RUN PHASE 2 CLINICAL TRIAL FOR ITS MONOCLONAL ANTIBODY DRUG BDB-001 IN TREATING PROGRESSIVE SEVERE COVID-19 INFECTION Source text in Chinese: bit.ly/2YFY3hV Further company coverage: (Reporting by Hong Kong newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below